Recent investigations have centered on the overlap of GLP-1|GIP|GCGR activator therapies and dopamine neurotransmission. While GCGR agonists are widely employed for managing type 2 T2DM, their unexpected consequences on reward circuits, specifically governed by dopaminergic systems, are gaining substantial interest. This article provides a summary